News Articles

Results from RE-SPECT CVT® published - first trial of NOAC in cerebral venous thrombosis INGELHEIM, Germany -Wednesday 4 September 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim today announced the publication of primary analysis from RE-SPECT CVT®, the first exploratory, prospective, randomised controlled study of a NOAC in patients with blood clots in the veins or venous sinuses of the brain. The trial investigated the safety...

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing... -Tuesday 3 September 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), have announced that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand. Boehringer Ingelheim and Zealand have a...

Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement... -Thursday 18 July 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung...

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel... -Monday 15 July 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead...

Dabigatran’s safety and efficacy established for management of VTE in children -Tuesday 9 July 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim today announced results from two paediatric studies of dabigatran etexilate, which were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia.1,2 The data showed dabigatran to be as effective...

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from... -Monday 1 July 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim and Yuhan Corporation today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule. The collaboration...

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα... -Tuesday 18 June 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of...

New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2... -Tuesday 11 June 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a new post-hoc analysis of data from the EMPA-REG OUTCOME® trial. These results indicated that the effect of empagliflozin on reducing cardiovascular and renal risk was consistent between a...

Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of... -Tuesday 11 June 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk.1 The...

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists -Wednesday 29 May 2019  

(BUSINESS WIRE) -- Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity. It will bring together Gubra’s established expertise in the design, synthesis, pharmaceutical characterization and in...

Trial results of Pradaxa® vs ASA in ESUS published in NEJM -Thursday 16 May 2019      

(BUSINESS WIRE) -- Boehringer Ingelheim today announced full results from the RE-SPECT ESUS® trial, a Phase III randomised, double-blind study investigating the efficacy and safety of Pradaxa® (dabigatran etexilate) versus acetylsalicylic acid (ASA) in preventing recurrent stroke in patients...

Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme -Monday 15 April 2019

• Boehringer Ingelheim plans a pilot programme using the innovative SoundTalksTM system in select pig barns • The goal is to harness the power of digital innovation and technological change to detect possible respiratory distress in swine quickly (BUSINESS WIRE)-- Boehringer Ingelheim...

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD -Monday 18 March 2019

Systemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue disease Pulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need1,2 Improving the lives of people...

Boehringer Ingelheim and GNA Biosolutions partner on emergency veterinary diagnostics development -Tuesday 26 February 2019

Programme could lead to new diagnostic solutions for African swine fever Boehringer Ingelheim demonstrates its focus on prevention and innovation yet again (BUSINESS WIRE)-- Boehringer Ingelheim and GNA Biosolutions announce that they have entered into a research collaboration focused...

Boehringer Ingelheim and Lilly’s CAROLINA® cardiovascular outcome trial for... -Thursday 14 February 2019  

Trajenta® demonstrates no increased cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk With a median follow-up of more than 6 years, CAROLINA® adds evidence to the long-term safety profile of Trajenta® in a broad range of adults with...

Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna -Friday 4 January 2019

(BUSINESS WIRE)-- Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target...

Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the... -Thursday 3 January 2019  

(BUSINESS WIRE)-- Science 37, an industry leader in virtual clinical trials, and Boehringer Ingelheim announced today a technology enterprise collaboration agreement that will support Boehringer Ingelheim in running remote clinical trials. Science 37 is licensing access to its proprietary...

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric... -Thursday 3 January 2019

(BUSINESS WIRE) -- Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors (GPCRs) known to engage in the...

American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and... -Tuesday 27 November 2018  

(BUSINESS WIRE) -- A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends empagliflozin as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with type 2 diabetes and established...

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies -Thursday 15 November 2018

(BUSINESS WIRE) -- Boehringer Ingelheim and Epizyme, Inc. (Nasdaq: EPZM) today announced a new global collaboration focused on the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies...